Literature DB >> 28637589

Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy.

Agustín Tortajada1, Eduardo Gutiérrez2, Elena Goicoechea de Jorge3, Jaouad Anter1, Alfons Segarra4, Mario Espinosa5, Miquel Blasco6, Elena Roman7, Helena Marco8, Luis F Quintana6, Josué Gutiérrez3, Sheila Pinto1, Margarita Lopez-Trascasa9, Manuel Praga10, Santiago Rodriguez de Córdoba11.   

Abstract

IgA nephropathy (IgAN), a frequent cause of chronic kidney disease worldwide, is characterized by mesangial deposition of galactose-deficient IgA1-containing immune complexes. Complement involvement in IgAN pathogenesis is suggested by the glomerular deposition of complement components and the strong protection from IgAN development conferred by the deletion of the CFHR3 and CFHR1 genes (ΔCFHR3-CFHR1). Here we searched for correlations between clinical progression and levels of factor H (FH) and FH-related protein 1 (FHR-1) using well-characterized patient cohorts consisting of 112 patients with IgAN, 46 with non-complement-related autosomal dominant polycystic kidney disease (ADPKD), and 76 control individuals. Patients with either IgAN or ADPKD presented normal FH but abnormally elevated FHR-1 levels and FHR-1/FH ratios compared to control individuals. Highest FHR-1 levels and FHR-1/FH ratios are found in patients with IgAN with disease progression and in patients with ADPKD who have reached chronic kidney disease, suggesting that renal function impairment elevates the FHR-1/FH ratio, which may increase FHR-1/FH competition for activated C3 fragments. Interestingly, ΔCFHR3-CFHR1 homozygotes are protected from IgAN, but not from ADPKD, and we found five IgAN patients with low FH carrying CFH or CFI pathogenic variants. These data support a decreased FH activity in IgAN due to increased FHR-1/FH competition or pathogenic CFH variants. They also suggest that alternative pathway complement activation in patients with IgAN, initially triggered by galactose-deficient IgA1-containing immune complexes, may exacerbate in a vicious circle as renal function deterioration increase FHR-1 levels. Thus, a role of FHR-1 in IgAN pathogenesis is to compete with complement regulation by FH.
Copyright © 2017 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CFH mutation; IgAN; complement alternative pathway; factor H; factor H-related proteins

Mesh:

Substances:

Year:  2017        PMID: 28637589     DOI: 10.1016/j.kint.2017.03.041

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  27 in total

Review 1.  CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Authors:  Peter F Zipfel; Thorsten Wiech; Emma D Stea; Christine Skerka
Journal:  J Am Soc Nephrol       Date:  2020-01-24       Impact factor: 10.121

2.  Detection of Genetic Rearrangements in the Regulators of Complement Activation RCA Cluster by High-Throughput Sequencing and MLPA.

Authors:  Jesús García-Fernández; Susana Vilches-Arroyo; Leticia Olavarrieta; Julián Pérez-Pérez; Santiago Rodríguez de Córdoba
Journal:  Methods Mol Biol       Date:  2021

3.  Correlation between IgAC3 ratio and oxford score in IgA nephropathy.

Authors:  Semahat Karahisar Şirali; Refika Büberci
Journal:  Clin Exp Nephrol       Date:  2022-06-23       Impact factor: 2.617

4.  Factor H-Related Protein 1 Drives Disease Susceptibility and Prognosis in C3 Glomerulopathy.

Authors:  Bárbara Márquez-Tirado; Josué Gutiérrez-Tenorio; Agustín Tortajada; Laura Lucientes Continente; Fernando Caravaca-Fontán; Talat H Malik; Raquel Roldán Montero; Sandra Elías; Ana Saiz Gonzalez; Gema Fernández-Juarez; Pilar Sánchez-Corral; Matthew C Pickering; Manuel Praga; Santiago Rodríguez de Córdoba; Elena Goicoechea de Jorge
Journal:  J Am Soc Nephrol       Date:  2022-05-11       Impact factor: 14.978

5.  Mesangial C3 deposition and serum C3 levels predict renal outcome in IgA nephropathy.

Authors:  Dan Wu; Xueqian Li; Xingfeng Yao; Nan Zhang; Lei Lei; Hejia Zhang; Mengmeng Tang; Jie Ni; Chen Ling; Zhi Chen; Xiangmei Chen; Xiaorong Liu
Journal:  Clin Exp Nephrol       Date:  2021-02-23       Impact factor: 2.801

Review 6.  The role of the alternative pathway of complement activation in glomerular diseases.

Authors:  Emilia Łukawska; Magdalena Polcyn-Adamczak; Zofia I Niemir
Journal:  Clin Exp Med       Date:  2018-02-15       Impact factor: 3.984

7.  Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases.

Authors:  Héctor Martin Merinero; Marta Subías; Amaia Pereda; Elena Gómez-Rubio; Lucia Juana Lopez; Constantino Fernandez; Elena Goicoechea de Jorge; Sonsoles Martin-Santamaria; Francisco Javier Cañada; Santiago Rodríguez de Córdoba
Journal:  Blood       Date:  2021-06-24       Impact factor: 22.113

8.  Complement Factor H-Related Protein 4A Is the Dominant Circulating Splice Variant of CFHR4.

Authors:  Richard B Pouw; Mieke C Brouwer; Anna E van Beek; Mihály Józsi; Diana Wouters; Taco W Kuijpers
Journal:  Front Immunol       Date:  2018-04-17       Impact factor: 7.561

9.  High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele CFHR3*B.

Authors:  Richard B Pouw; Irene Gómez Delgado; Alberto López Lera; Santiago Rodríguez de Córdoba; Diana Wouters; Taco W Kuijpers; Pilar Sánchez-Corral
Journal:  Front Immunol       Date:  2018-04-24       Impact factor: 7.561

10.  Progressive IgA Nephropathy Is Associated With Low Circulating Mannan-Binding Lectin-Associated Serine Protease-3 (MASP-3) and Increased Glomerular Factor H-Related Protein-5 (FHR5) Deposition.

Authors:  Nicholas R Medjeral-Thomas; Anne Troldborg; Nicholas Constantinou; Hannah J Lomax-Browne; Annette G Hansen; Michelle Willicombe; Charles D Pusey; H Terence Cook; Steffen Thiel; Matthew C Pickering
Journal:  Kidney Int Rep       Date:  2017-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.